Factores asociados a respuesta virológica en mujeres que usaron profilaxis antirretroviral de gran actividad para transmisión materno-fetal del virus de la inmunodeficiencia humana tipo 1

dc.contributor.authorPalacios, Ricardo [UNIFESP]
dc.contributor.authorSenise, Jorge Figueiredo [UNIFESP]
dc.contributor.authorVaz, Maria José Rodrigues [UNIFESP]
dc.contributor.authorCastelo Filho, Adauto [UNIFESP]
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.date.accessioned2018-06-15T17:17:29Z
dc.date.available2018-06-15T17:17:29Z
dc.date.issued2008-08-01
dc.description.abstractINTRODUCTION. Pregnancy is the only circumstance in HIV infection requiring urgent virological response to the antiviral approach because of the influence of plasma viral load (VL) on mother-to-child transmission (MCT) of the disease. This study analyzes factors related to the time needed to reach VL < 400 copies/mL during antiretroviral prophylaxis for MCT.METHODS. The study included a cohort of HIV-1 infected pregnant women enrolled between 2000 and 2005 with baseline CD4+ lymphocyte count > 300 cells/mu L, highly-active antiretroviral prophylaxis for at least 4 weeks, antiretroviral interruption after delivery, and available laboratory data.RESULTS. Seventy-five pregnancies were analyzed. Median baseline VL was 3.71 log(10) copies/mL and CD4+ count was 573 cells/mu L. Prophylaxis started after 26.6 weeks of gestation and lasted up to 11.7 weeks in 75% of cases. The prophylactic regimen was changed in 12 pregnancies, 7 because of toxicity. A protease inhibitor was included in 33 prophylactic regimens, 11 of them with lopinavir. Prophylaxis resulted in undetectable HIV-1 VL within 6.7 weeks in 75% of pregnancies. VL was detectable at the end of prophylaxis in 5 cases. Time to undetectable VL was shorter if baseline VL was less than 100,000 copies/mL and the antiretroviral regimen was not changed during prophylaxis.CONCLUSIONS. To achieve VL < 400 copies/mL at delivery, antiretroviral prophylaxis should be started before 26 to 28 weeks of pregnancy. A potent and well-tolerated prophylactic antiretroviral regimen will likely reduce the time to virological response. Trials investigating alternative regimens (e.g., lopinavir-containing) for patients with late diagnosis during prenatal care or VL >100,000 copies/mL are warranted.en
dc.description.affiliationUniv Fed Sao Paulo, Lab Retrovirol, Disciplina Infectol, NUPAIG, BR-04039032 Sao Paulo, Brazil
dc.description.affiliationUnifespUniv Fed Sao Paulo, Lab Retrovirol, Disciplina Infectol, NUPAIG, BR-04039032 Sao Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extent411-415
dc.identifierhttps://dx.doi.org/10.1157/13125637
dc.identifier.citationEnfermedades Infecciosas Y Microbiologia Clinica. Barcelona: Ediciones Doyma S A, v. 26, n. 7, p. 411-415, 2008.
dc.identifier.doi10.1157/13125637
dc.identifier.issn0213-005X
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/43542
dc.identifier.wosWOS:000259328600003
dc.language.isospa
dc.publisherEdiciones Doyma S A
dc.relation.ispartofEnfermedades Infecciosas Y Microbiologia Clinica
dc.rightsAcesso aberto
dc.subjectmother-to-child transmissionen
dc.subjectprophylaxis.en
dc.subjectantiretroviralsen
dc.subjectHIV-1en
dc.subjectviral loaden
dc.subjectpregnancyen
dc.titleFactores asociados a respuesta virológica en mujeres que usaron profilaxis antirretroviral de gran actividad para transmisión materno-fetal del virus de la inmunodeficiencia humana tipo 1es
dc.title.alternativeFactors associated with virological response in women receiving highly-active antiretroviral prophylaxis for HIV-1 mother-to-child transmissionen
dc.typeArtigo
Arquivos
Coleções